GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Public ClinicalTrials.gov record NCT02224703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.
Study identification
- NCT ID
- NCT02224703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Interventions
- GWP42003-P Drug
- Placebo Control Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2015
- Primary completion
- Apr 8, 2018
- Completion
- Apr 8, 2018
- Last update posted
- Sep 27, 2022
2015 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 20
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Little Rock | Arkansas | 72202 | — |
| Not listed | Los Angeles | California | 90027 | — |
| Not listed | Sacramento | California | 95816 | — |
| Not listed | Hartford | Connecticut | 06106 | — |
| Not listed | Miami | Florida | 33155 | — |
| Not listed | Savannah | Georgia | 31404 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Lexington | Kentucky | 40536-0284 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Saint Paul | Minnesota | 55102 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Omaha | Nebraska | 68106 | — |
| Not listed | Lebanon | New Hampshire | 03756 | — |
| Not listed | Buffalo | New York | 14203 | — |
| Not listed | Chapel Hill | North Carolina | 27599 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Philadelphia | Pennsylvania | 19104-4399 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Austin | Texas | 78723 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Richmond | Virginia | 23298-0211 | — |
| Not listed | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02224703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02224703 live on ClinicalTrials.gov.